Surface Biofunctionalization of Tissue Engineered for the Development of Biological Heart Valves: A Review
Source abstract
Abstract
Valve replacement is the mainstay of treatment for end-stage valvular heart disease, but varying degrees of defects exist in clinically applied valve implants. A mechanical heart valve requires long-term anti-coagulation, but the formation of blood clots is still inevitable. A biological heart valve eventually decays following calcification due to glutaraldehyde cross-linking toxicity and a lack of regenerative capacity. The goal of tissue-engineered heart valves is to replace normal heart valves and overcome the shortcomings of heart valve replacement commonly used in clinical practice. Surface biofunctionalization has been widely used in various fields of research to achieve functionalization and optimize mechanical properties. It has been applied to the study of tissue engineering in recent years. It is proposed to improve the shortcomings of the current commercial valve, but it still faces many challenges. This review aimed to summarize the modification strategies of biofunctionalization of biological heart valve surfaces based on tissue engineering to eliminate adverse reactions that occur clinically after implantation. Finally, we also proposed the current challenges and possible directions for future research.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Electrospun Nanofibers in Biomedical Applications · Cardiac Valve Diseases and Treatments · Tissue Engineering and Regenerative Medicine
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Cardiovascular Surgery, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Road, Nanchang 330006, China
Department of Cardiovascular Surgery, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan 430071, China
Funding
Natural Science Foundation of Jiangxi Province · National Natural Science Foundation of China · Natural Science Foundation of Jiangxi, China
References (100+)
Show source-provided references
1. Prevalence of aortic valve abnormalities in the elderly: An echocardiographic study of a random population sample10.1016/0735-1097(93)90249-Z ↗
2. Mechanical and surgical bioprosthetic valve thrombosis
3. Corrigendum to: 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)10.1093/eurheartj/ehab395 ↗
4. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines10.1016/j.jacc.2021.12.012 ↗
5. Mechanical versus bioprosthetic valve for aortic valve replacement: Systematic review and meta-analysis of reconstructed individual participant data10.1093/ejcts/ezac268 ↗
6. EMT-Inducing Biomaterials for Heart Valve Engineering: Taking Cues from Developmental Biology10.1007/s12265-011-9300-4 ↗
7. Bioengineering Challenges for Heart Valve Tissue Engineering10.1146/annurev-bioeng-061008-124903 ↗
8. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses10.1161/01.CIR.89.2.635 ↗
9. Calcification of Tissue Heart Valve Substitutes: Progress Toward Understanding and Prevention10.1016/j.athoracsur.2004.06.033 ↗
10. Heart valve tissue engineering: An overview of heart valve decellularization processes10.2217/rme-2017-0061 ↗
11. Developing a Clinically Relevant Tissue Engineered Heart Valve—A Review of Current Approaches10.1002/adhm.201700918 ↗
12. Body surface area as a predictor of aortic and pulmonary valve diameter10.1016/S0022-5223(00)70092-4 ↗
13. Human semilunar cardiac valve remodeling by activated cells from fetus to adult: Implications for postnatal adaptation, pathology, and tissue engineering10.1161/CIRCULATIONAHA.105.591768 ↗
14. Micromechanics of the fibrosa and the ventricularis in aortic valve leaflets10.1016/0021-9290(92)90249-Z ↗
15. Heart valve function: A biomechanical perspective10.1098/rstb.2007.2122 ↗
16. Drug delivery in aortic valve tissue engineering10.1016/j.jconrel.2014.10.009 ↗
17. Cell-laden microengineered gelatin methacrylate hydrogels10.1016/j.biomaterials.2010.03.064 ↗
18. Valvulogenesis: The moving target10.1098/rstb.2007.2130 ↗
19. The Emerging Role of Valve Interstitial Cell Phenotypes in Regulating Heart Valve Pathobiology10.2353/ajpath.2007.070251 ↗
20. Biodegradable and biomimetic elastomeric scaffolds for tissue-engineered heart valves10.1016/j.actbio.2016.10.032 ↗
21. Heart valve tissue engineering: How far is the bedside from the bench?10.1017/erm.2015.15 ↗
22. Surface Modification of Polyacrylonitrile Membrane by Chemical Reaction and Physical Coating: Comparison between Static and Pore-Flowing Procedures10.1021/acsomega.7b02094 ↗
23. Porous Polypropylene Membranes with Different Carboxyl Polymer Brush Layers for Reversible Protein Binding via Surface-Initiated Graft Copolymerization10.1021/cm0485714 ↗
24. Polymer brushes via surface-initiated controlled radical polymerization: Synthesis, characterization, properties, and applications10.1021/cr900045a ↗
25. Performance of a physically adsorbed high-molecular-mass polyethyleneimine layer as coating for the separation of basic proteins and peptides by capillary electrophoresis10.1016/0021-9673(95)00394-3 ↗
26. Surface chemistry and aspect ratio mediated cellular uptake of Au nanorods10.1016/j.biomaterials.2010.06.051 ↗
27. Synthesis, Surface Modification and Characterisation of Biocompatible Magnetic Iron Oxide Nanoparticles for Biomedical Applications10.3390/molecules18077533 ↗
28. Chemical Surface Modification of Polymeric Biomaterials for Biomedical Applications10.1002/marc.201900430 ↗
29. The effects of cross-link density and chemistry on the calcification potential of diamine-extended glutaraldehyde-fixed bioprosthetic heart-valve materials10.1042/BA20090101 ↗
30. Synthesis of aldehydes and their interactions during the in vitro aging of collagen10.1021/bi00788a025 ↗
31. Biological factors affecting long-term results of valvular heterografts10.1016/S0022-5223(19)42561-0 ↗
32. The role of glutaraldehyde-induced cross-links in calcification of bovine pericardium used in cardiac valve bioprostheses
33. Immunogenicity of glutaraldehyde-tanned bovine pericardium10.1016/S0022-5223(20)31465-3 ↗
34. Phagocytosis and intracellular digestion of collagen, its role in turnover and remodelling10.1007/BF02409011 ↗
35. Leukocytes, platelets, and surface microstructure of spontaneously degen-erated porcine bioprosthetic valves10.1111/j.1540-8191.1988.tb00246.x ↗
36. Bioprosthetic heart valves: Modes of failure10.1111/j.1365-2559.2008.03190.x ↗
37. Porcine bioprosthetic heart valves: The next generation10.1016/j.ahj.2012.05.011 ↗
38. Physical properties of a porcine internal thoracic artery fixed with an epoxy compound10.1016/S0142-9612(96)00081-6 ↗
39. Biocompatibility and calcification of bovine pericardium employed for the construction of cardiac bioprostheses treated with different chemical crosslink methods
40. In vitro degradation of dermal sheep collagen cross-linked using a water-soluble carbodiimide10.1016/0142-9612(96)86737-8 ↗
41. EDC/NHS-crosslinked type II collagen-chondroitin sulfate scaffold: Characterization and in vitro evaluation10.1007/s10856-007-3281-5 ↗
42. Crosslinking strategies for preparation of extracellular matrix-derived cardiovascular scaffolds10.1093/rb/rbu009 ↗
43. Cross-Linking Methacrylated Porcine Pericardium by Radical Polymerization Confers Enhanced Extracellular Matrix Stability, Reduced Calcification, and Mitigated Immune Response to Bioprosthetic Heart Valves10.1021/acsbiomaterials.9b00091 ↗
44. Radical polymerization-crosslinking method for improving extracellular matrix stability in bioprosthetic heart valves with reduced potential for calcification and inflammatory response10.1016/j.actbio.2018.10.017 ↗
45. Crosslinking porcine aortic valve by radical polymerization for the preparation of BHVs with improved cytocompatibility, mild immune response, and reduced calcification10.1177/0885328220984066 ↗
46. Procyanidins-crosslinked heart valve matrix: Anticalcification effect10.1002/jbm.b.31363 ↗
47. Crosslinking of decellularized porcine heart valve matrix by procyanidins10.1016/j.biomaterials.2006.02.008 ↗
48. Curcumin-crosslinked acellular bovine pericardium for the application of calcification inhibition heart valves10.1088/1748-605X/ab6f46 ↗
49. Quercetin-crosslinked porcine heart valve matrix: Mechanical properties, stability, anticalcification and cytocompatibility10.1016/j.actbio.2009.07.035 ↗
50. Gelatinases in soft tissue biomaterials. Analysis of different crosslinking agents10.1016/S0142-9612(02)00054-6 ↗
51. Effect of diphosphonate binding to collagen upon inhibition of calcification and pro-motion of spontaneous endothelial cell coverage on tissue valve prostheses
52. Influence of different chemical cross-linking treatments on the properties of bovine pericardium and collagen10.1016/S0142-9612(98)90205-8 ↗
53. Periodate-mediated glycosaminoglycan stabilization in bioprosthetic heart valves10.1002/1097-4636(20010915)56:4<478::AID-JBM1119>3.0.CO;2-C ↗
54. Cross-linking characteristics of biological tissues fixed with monofunctional or multi-functional epoxy compounds10.1016/0142-9612(96)87282-6 ↗
55. Crosslinking characteristics and mechanical properties of a bovine peri-cardium fixed with a naturally occurring crosslinking agent10.1002/(SICI)1097-4636(199911)47:2<116::AID-JBM2>3.0.CO;2-J ↗
56. Glutaraldehyde as a fixative in bioprostheses and drug delivery matrices10.1016/0142-9612(96)82721-9 ↗
57. In vivo behavior of epoxy-crosslinked porcine heart valve cusps and walls10.1002/(SICI)1097-4636(2000)53:1<18::AID-JBM3>3.0.CO;2-J ↗
58. Characterization of porous collagen/hyaluronic acid scaffold modified by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide cross-linking10.1016/S0142-9612(01)00235-6 ↗
59. Inorganic-polymerization crosslinked tissue-siloxane hybrid as potential biomaterial for bioprosthetic heart valves10.1002/jbm.a.37061 ↗
60. Dialdehyde pectin-crosslinked and hirudin-loaded decellularized porcine pericardium with improved matrix stability, enhanced anti-calcification and anticoagulant for bioprosthetic heart valves10.1039/D1BM01297E ↗
61. Nonglutaraldehyde Fixation for off the Shelf Decellularized Bovine Pericardium in Anticalcification Cardiac Valve Applications10.1021/acsbiomaterials.8b01311 ↗
62. Visible light-induced cross-linking of porcine pericardium for the improvement of endotheli-alization, anti-tearing, and anticalcification properties10.1002/jbm.a.37263 ↗
63. In vivo biomechanical assessment of triglyc-idylamine crosslinked pericardium10.1016/j.biomaterials.2007.08.021 ↗
64. Triglycidyl Amine Crosslinking Combined with Ethanol Inhibits Bioprosthetic Heart Valve Calcification10.1016/j.athoracsur.2011.04.104 ↗
65. Mechanisms of the in vivo inhibition of calcification of bioprosthetic porcine aortic valve cusps and aortic wall with triglycidylamine/mercapto bisphosphonate10.1016/j.biomaterials.2006.09.029 ↗
66. Triglycidylamine Crosslinking of Porcine Aortic Valve Cusps or Bovine Pericardium Results in Improved Biocompatibility, Biomechanics, and Calcification Resistance: Chemical and Biological Mechanisms10.1016/S0002-9440(10)62227-4 ↗
67. Tissue Engineering of Pulmonary Heart Valves on Allogenic Acellular Matrix Conduits: In Vivo Restoration of Valve Tissue10.1161/circ.102.suppl_3.III-50 ↗
68. Tissue engineering of cardiac valve prostheses I: Development and histological char-acterization of an acellular porcine scaffold
69. Tissue engineering of cardiac valve prostheses II: Biomechanical characterization of decellularized porcine aortic heart valves
70. Construction of autologous human heart valves based on an acellular allograft matrix10.1161/01.cir.0000032900.55215.85 ↗
71. Early failure of the tissue engineered porcine heart valve SYNERGRAFT™ in pediatric patients10.1016/S1010-7940(03)00094-0 ↗
72. Fibrin as a cell carrier in cardiovascular tissue engineering applications10.1016/j.biomaterials.2004.08.007 ↗
73. In Vivo Remodeling and Structural Characterization of Fibrin-Based Tissue-Engineered Heart Valves in the Adult Sheep Model10.1089/ten.tea.2009.0018 ↗
74. Crosslinked hyaluronan scaffolds as a biologically active carrier for valvular interstitial cells10.1016/j.biomaterials.2004.07.018 ↗
75. Flexural characterization of cell encapsulated PEGDA hydrogels with applications for tissue engineered heart valves10.1016/j.actbio.2011.02.018 ↗
76. Fabrication and Mechanical Evaluation of Anatomically-Inspirei Quasilaminate Hydrogel Structures with Layer-Specific Formulations10.1007/s10439-012-0666-5 ↗
77. Design and manufacture of a polyvinyl alcohol (PVA) cryogel tri-leaflet heart valve prosthesis10.1016/j.medengphy.2003.10.007 ↗
78. A collagen-glycosaminoglycan co-culture model for heart valve tissue engineering applications10.1016/j.biomaterials.2005.10.031 ↗
79. Hybrid Pericardium with VEGF-Loaded Hyaluronic Acid Hydrogel Coating to Improve the Biological Properties of Bioprosthetic Heart Valves10.1002/mabi.201800390 ↗
80. Vascular endothelial growth factor-loaded elastin-hydrogel modification of the pericardium im-proves endothelialization potential of bioprosthetic heart valves10.1177/0885328219854336 ↗
81. Fucoidan/VEGF-based surface modification of decellularized pulmonary heart valve improves the antithrombotic and re-endothelialization potential of bioprostheses10.1016/j.biomaterials.2018.01.054 ↗
82. Zwitterionic hydrogel-coated heart valves with improved endothelialization and anti-calcification properties10.1016/j.msec.2021.112329 ↗
83. Engineering of a polymer layered bio-hybrid heart valve scaffold10.1016/j.msec.2015.03.009 ↗
84. Double-Network Hydrogel Armored Decellularized Porcine Pericardium as Durable Bioprosthetic Heart Valves10.1002/adhm.202102059 ↗
85. Modifying decellularized aortic valve scaffolds with stromal cell-derived factor-1α loaded proteolytically degradable hydrogel for recellularization and remodeling10.1016/j.actbio.2019.02.002 ↗
86. Anticalcification Potential of POSS-PEG Hybrid Hydrogel as a Scaffold Material for the Devel-opment of Synthetic Heart Valve Leaflets10.1021/acsabm.0c01544 ↗
87. Optimizing Glutaralde-hyde-Fixed Tissue Heart Valves with Chondroitin Sulfate Hydrogel for Endothelialization and Shielding against Deterioration10.1021/acs.biomac.8b00077 ↗
88. Paris, J.L., and Vallet-Regí, M. (2020). Mesoporous Silica Nanoparticles for Co-Delivery of Drugs and Nucleic Acids in Oncology: A Review. Pharmaceutics, 12.10.3390/pharmaceutics12060526 ↗
89. Alnylam prepares to land first RNAi drug approval10.1038/nrd.2018.20 ↗
90. CPX-351: A nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties10.2147/IJN.S139450 ↗
91. Polymer nanoparticles10.1016/B978-0-12-416020-0.00007-3 ↗
92. Mesoporous silica nanoparticles for drug and gene delivery10.1016/j.apsb.2018.01.007 ↗
93. Vallet-Regí, M., Colilla, M., Izquierdo-Barba, I., and Manzano, M. (2018). Mesoporous Silica Nanoparticles for Drug Delivery: Current Insights. Molecules, 23.10.3390/molecules23010047 ↗
94. Development of Metal Nanoparticle Catalysis toward Drug Discovery10.1248/cpb.c19-00157 ↗
95. Application of decellularized scaffold combined with loaded nanoparticles for heart valve tissue engineering in vitro10.1007/s11596-011-0156-2 ↗
96. Surface biofunctionalization of the decellularized porcine aortic valve with VEGF-loaded nano-particles for accelerating endothelialization10.1016/j.msec.2018.12.079 ↗
97. Heart Valves Cross-Linked with Erythrocyte Membrane Drug-Loaded Nanoparticles as a Biomimetic Strategy for Anti-coagulation, Anti-inflammation, Anti-calcification, and Endothelialization10.1021/acsami.0c12688 ↗
98. Drug delivery from ordered mesoporous matrices10.1517/17425240903304024 ↗
99. New developments in ordered mesoporous materials for drug delivery10.1039/b922651f ↗
100. Sustained delivery of siRNA/mesoporous silica nanoparticle complexes from nanofiber scaf-folds for long-term gene silencing10.1016/j.actbio.2018.05.054 ↗